Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease)... Show more
Alaunos Therapeutics (formerly ZIOPHARM Oncology) has historically been a clinical-stage developer of T-cell receptor (TCR-T) cell therapies for solid tumors. That legacy is now winding down in favor of a fundamentally different strategic identity centered on cardiometabolic and cardiopulmonary disease. The October 2026 acquisition of Velaris Therapeutics brings a portfolio of ActRII-Fc ligand traps and an anti-PDGF-B antibody designed to correct the signaling imbalances that drive pulmonary vascular remodeling — the same validated pharmacology behind recently approved PAH therapies.
Structurally, the company now holds two early-stage franchises: a cardiopulmonary biologic pipeline (VLR199, VLR360, VLR247, VLR258) and a preclinical oral small-molecule obesity program (ALN1003). This positions Alaunos within two of biotechnology's most capital-intensive and competitive therapeutic arenas, where differentiation hinges on mechanism and clinical translation. The non-hormonal, non-incretin design of ALN1003 is intended to offer a simpler oral alternative to injectable GLP-1 (glucagon-like peptide-1) therapies, but it remains unproven in humans. Medium-term, the company's competitive position will depend less on current market share — it generates no product revenue — and more on whether its scientific platform can attract validation and future partnerships.
The dominant forward-looking catalyst is clinical execution on the newly acquired Velaris assets. Management has signaled that proof-of-concept datasets for VLR199 and VLR360 are not expected until approximately 2028, meaning near-term trading will hinge on operational milestones rather than pivotal data. Supporting catalysts include early regulatory submissions for VLR247 and VLR258 and any progress toward an IND filing for ALN1003.
Capital-allocation and balance-sheet developments remain equally important. The roughly $350 million private placement — backed by Fairmount alongside investors including Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, and Wellington Management — extends projected runway into 2029 and was central to regaining Nasdaq compliance. Financing structure and potential future dilution will be closely watched. On the sentiment side, coverage is thin and the consensus has leaned cautious; the single-digit market capitalization and limited institutional research mean that a single rating change, price-target revision, or initiation of coverage could produce outsized swings in investor perception. Any new analyst initiations following the strategic reset would be a notable signal to monitor.
Alaunos's trajectory is tightly linked to the broader biotechnology financing cycle. Higher-for-longer interest rates and tighter risk appetite have historically pressured pre-revenue developers by raising the cost of capital and lowering the valuations assigned to long-dated, speculative pipelines. The Velaris financing was a reminder that well-structured transactions can still clear, but future capital needs will remain sensitive to the rate environment and to biotech investor sentiment.
On the demand side, the obesity and metabolic-disease market continues to expand rapidly, driven by rising prevalence and the commercial success of incretin-based therapies. Any oral, non-hormonal alternative that demonstrates safety and durable efficacy would address a substantial unmet need. In PAH, the emergence of activin-signaling inhibitors has validated the mechanistic pathway Alaunos's ActRII-Fc candidates target, while also intensifying competition from larger, well-capitalized rivals. Regulatory climate, reimbursement dynamics for novel cardiometabolic drugs, and geopolitical factors affecting clinical supply chains round out the macro backdrop.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. Designed to surface developing trends, it supports users in evaluating possible breakouts or reversals and in exploring predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to help users track shifting signals over time. For investors monitoring a micro-cap name such as Alaunos Therapeutics, where sentiment can shift quickly, tools of this kind can offer an additional, data-driven layer of context alongside fundamental research.
Looking toward 2026 and beyond, Alaunos's investment narrative is defined by transformation rather than near-term revenue. The strategic pivot consolidates two high-potential but unproven franchises, and the company's multi-year cash runway provides the time needed to advance them. The critical watchpoints are scientific: whether VLR199 and VLR360 can demonstrate clinical proof of concept in cardiopulmonary disease, and whether ALN1003 can translate encouraging preclinical results into a viable oral metabolic therapy.
Longer-term themes include potential market expansion into adjacent cardiometabolic indications, the evolution of the cost structure as programs move from discovery into clinical development, and the sustainability of any future margins in a market dominated by larger competitors. Competitive threats from established obesity and PAH franchises, regulatory developments, and future capital-allocation decisions — including partnerships, licensing, or additional financings — will all shape sentiment. Consensus expectations remain limited and cautious, and any external price targets should be read as analyst opinions rather than forecasts. The company's ability to convert a newly fortified balance sheet into validated clinical data will ultimately determine whether the strategic reset translates into durable shareholder value.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TCRT has been loosely correlated with BRTX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRT jumps, then BRTX could also see price increases.
| Ticker / NAME | Correlation To TCRT | 1D Price Change % | ||
|---|---|---|---|---|
| TCRT | 100% | +4.40% | ||
| BRTX - TCRT | 33% Loosely correlated | -19.23% | ||
| XBIO - TCRT | 32% Poorly correlated | -6.49% | ||
| PRME - TCRT | 31% Poorly correlated | -7.55% | ||
| KPRX - TCRT | 29% Poorly correlated | -11.10% | ||
| STOK - TCRT | 29% Poorly correlated | -0.45% | ||
More | ||||
a cancer treatment company
Industry Biotechnology
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.